EN DE

IHH Healthcare Berhad, an investment holding company, (5225) Fair Value & Analysis

Healthcare · MY · Market cap 75.1B MYR

IH IHH Healthcare Berhad, an investment holding company, 5225 · KLSE
Price8.27 MYR
Fair Value4.61 MYR
Upside-44.3%
Quality50/100
Watch IHH Healthcare Berhad, an investment holding company, for free, get notified when fair value or trend changes. Watch for free
Healthy Growth
Thin margins · 8.1% net margin
Low debt · generates free cash flow
1.23% dividend yield
Mixed vs. peers (7/15)
Moderate moat 47/100
Evidence: Medium Range 2.76 MYR – 6.21 MYR Share as image

Fair value as of: Aug 13, 2026

From 26 valuation models · updated today

Share price −2.1% over the past month.

A solid business, but screening 44% overvalued on our models.

What matters now

  • The price sits above even our optimistic bull case (6.21 MYR). The favourable scenario is already priced in.
  • Solid but not exceptional quality (50/100) and above fair value, neither a clear bargain nor a standout compounder.
  • A fairly wide model range (2.76 MYR to 6.21 MYR) leaves room in how you read the outcome.
Share this valuation: 𝕏 WhatsApp

Price vs Fair Value (5 years)

9.33 MYR 4.77 MYR Fair Value 4.61 MYR Mar 2021 Aug 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 13, 2026.

How to read this chart

60‑month range 4.77 MYR – 9.33 MYR · fair‑value band 2.76 MYR – 6.21 MYR · the 8.27 MYR price screens above the 4.61 MYR fair value. Dashed = 300-day average. As of Aug 13, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

IHH Healthcare Berhad, an investment holding company, (5225) currently trades at 8.27 MYR, while our model-based Fair Value estimate is 4.61 MYR, implying the stock looks roughly 44.3% overvalued today. The Quality Score stands at 50/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: medium).

Over the trailing twelve months, IHH Healthcare Berhad, an investment holding company, generated revenue of 26.0B MYR at a net margin of 8.1%. Revenue grew 4.1% year over year. It earns a return on equity of 7.9%. Net debt stands at 15.9B MYR. Fundamentals as of Aug 13, 2026

Our scenario range runs from 2.76 MYR (bear case) to 6.21 MYR (bull case); at 8.27 MYR, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 21% below its 52-week high and 30% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -14% fair-value upside, at -44%, 5225 screens richer than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Model Bear Bear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull Bull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence
Highest evidence
Growth DCF 1.68 MYR 3.57 MYR 6.83 MYR 80
Residual Income 2.78 MYR 2.93 MYR 3.13 MYR 76
Rev-Margin DCF 2.40 MYR 5.03 MYR 8.50 MYR 74
All 26 models by family
DCF Models
FCF DCF 1.71 MYR 3.81 MYR 7.55 MYR 38
Owner Earnings 0.1500 MYR 0.8900 MYR 2.21 MYR 31
5Y Revenue Exit 2.40 MYR 5.14 MYR 8.95 MYR 39
5Y EBITDA Exit 4.03 MYR 8.56 MYR 14.41 MYR 41
5Y P/E Exit 2.56 MYR 5.47 MYR 8.88 MYR 38
10Y Revenue Exit 2.04 MYR 4.58 MYR 8.67 MYR 36
10Y EBITDA Exit 3.24 MYR 7.12 MYR 13.34 MYR 37
10Y P/E Exit 2.26 MYR 4.83 MYR 8.61 MYR 35
Earnings-Based
Graham-Dodd 1.62 MYR 8.03 MYR 11.08 MYR 54
Lynch FV 2.17 MYR 3.10 MYR 4.02 MYR 50
PEG = 1.0 2.17 MYR 3.10 MYR 4.02 MYR 46
EPV 2.01 MYR 2.46 MYR 2.85 MYR 59
Dividend Discount
Gordon GGM 0.9600 MYR 2.00 MYR 3.18 MYR 70
DDM Multi-Stage 0.9600 MYR 1.69 MYR 2.10 MYR 61
Multiples
P/E Multiple 3.92 MYR 5.23 MYR 6.54 MYR 63
P/S Multiple 3.03 MYR 4.04 MYR 5.05 MYR 58
P/B Multiple 3.03 MYR 4.04 MYR 5.05 MYR 55
EV/EBIT 4.11 MYR 5.71 MYR 7.31 MYR 53
EV/EBITDA 5.53 MYR 7.61 MYR 9.68 MYR 54
EV/Revenue 2.73 MYR 4.20 MYR 5.67 MYR 43
Asset-Based
NCAV (Graham) 1.71 MYR 2.30 MYR 3.43 MYR 50
Growth DCF
Growth DCF 1.68 MYR 3.57 MYR 6.83 MYR 80
Rev-Margin DCF 2.40 MYR 5.03 MYR 8.50 MYR 74
Economic Profit
Residual Income 2.78 MYR 2.93 MYR 3.13 MYR 76
ROIC Compounder 2.01 MYR 2.46 MYR 2.85 MYR 72
Growth Earnings
Growth-Adj P/E 3.41 MYR 4.87 MYR 6.33 MYR 68

Widest divergence: Growth Earnings (4.87 MYR) versus Dividend Discount (1.69 MYR). Highest evidence: Growth DCF (80).

Notify me when 5225 reaches fair value

Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.

Key figures & financial health

Revenue (TTM) 26.0B MYR
Revenue growth (YoY) +4.1%
Net margin 8.1%
Return on equity 7.9%
Free cash flow 1.6B MYR FY2025
P/E ratio 34.5
More key figures
Operating margin 14.5%
EPS (TTM) 0.2400 MYR
Dividend yield 1.2%
EPS growth (YoY) +2.5%
Net debt 15.9B MYR FY2025

Figures from reported company fundamentals · as of Aug 13, 2026. TTM = trailing twelve months.

Quality Score breakdown

Overall quality 50/100

Of which business quality 50 · Market factors (momentum, volatility) 61

Profitability 32
Margins and returns on capital today
Quality Growth 27
Are margins and returns improving?
Cashflow 52
Earnings quality: real cash, not paper profit
Fin. Strength 55
Balance sheet, leverage, solvency risk
Investment 61
Disciplined investing over empire-building
Low Volatility 95
Calm price path (market factor)
Momentum 44
Price trend over the last 3–12 months (market factor)
52W Momentum 51
Distance to the 52-week high (market factor)
Net Issuance 80
Buybacks instead of dilution

Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.

About the company

IHH Healthcare Berhad, an investment holding company, offers healthcare services in Malaysia, Singapore, Turkey, India, China, Japan, Europe, and internationally. It provides primary care services, such as outpatient treatment, check-ups, vaccinations, preventive care, and patient education services.

Full company description

IHH Healthcare Berhad, an investment holding company, offers healthcare services in Malaysia, Singapore, Turkey, India, China, Japan, Europe, and internationally. It provides primary care services, such as outpatient treatment, check-ups, vaccinations, preventive care, and patient education services. The company also offers secondary care facilities, including medical emergencies and acute treatment, as well as specialist consultation, diagnostics, and lab services; tertiary care services comprising specialist consultative care, advanced treatment, complex surgery, and inpatient care services; and quaternary care services, such as organ transplants, neurosurgery, cardiac surgery, and reconstructive plastic surgery. In addition, it provides ancillary services, including diagnostics, laboratory testing, radiology, physiotherapy, and integrated rehabilitation and advanced molecular diagnostics services. Further, the company offers medical education; train and develop nurses, doctors, clinicians, and allied healthcare professionals; administrative, management, consultancy services; emergency, home, and ambulatory care services; healthcare information systems, web-based applications, and other technology solutions; and real estate investment trust services. Additionally, it provides services for medical diagnostic laboratory tests; develops, constructs, and leases medical facility buildings and healthcare facilities; provides catering, laundry, and cleaning services for hospitals; and haemodialysis services, as well as imports and wholesales drug and medical materials. The company engages in the letting of properties; and computer software designing, development, customization, integration, implementation, maintenance, and related services. IHH Healthcare Berhad was incorporated in 2010 and is based in Kuala Lumpur, Malaysia.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

IHH Healthcare Berhad, an investment holding company, reported revenue of 25.7B MYR in FY2025 versus 17.1B MYR in FY2021, a compound +10.7%/yr. Reported net income was 2.1B MYR in FY2025, compounding +3.1%/yr from FY2021.

Growth Quality 85/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Latest Revenue (FY 2025)
25.7B MYR
Latest YoY
+5.6%
Avg. growth/yr (3Y) Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+12.7%
Avg. growth/yr (5Y) Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+14.0%
Avg. growth/yr (16Y) Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+12.4%
Revenue +10.7%/yr
FY21 17.1B MYR
FY22 18.0B MYR
FY23 20.9B MYR
FY24 24.4B MYR
FY25 25.7B MYR
Net income +3.1%/yr
FY21 1.9B MYR
FY22 1.5B MYR
FY23 3.0B MYR
FY24 2.7B MYR
FY25 2.1B MYR
Character of growth · EPS growth decomposed (2014-2025) +13.5 % p.a.
Revenue per share +11.0 pp

of which total revenue +11.9 pp · buybacks/dilution −0.9 pp

EBIT margin +0.0 pp
Tax rate +0.4 pp
Residual (interest, one-offs) +2.1 pp

Absolute contributions in percentage points per year; they sum to the EPS growth rate. Start and end points are 3-year averages (details on hover).

5225 screens 44% overvalued. Compare with HCA Healthcare, Inc →

Share or link this analysis
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Cite: Fair Value Calculator (2026). "IHH Healthcare Berhad, an investment holding company, Fair Value". https://www.fairvalue-calculator.com/stock/5225

Peer Group

Medical Care Facilities · 265 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Quality Score 50 · Below median
Fair Value upside −44% · Bottom 25%
Return on equity (TTM) 8% · Above median
Return on assets 4% · Above median
Net margin (TTM) 8% · Above median
Operating margin (TTM) 15% · Top 25%
Revenue growth 4% · Below median
Dividend yield (TTM) 1.2% · Below median
Debt / equity 0.26× · Higher than median

Valuation Multiples vs Medical Care Facilities median · lower = cheaper

P/E (TTM) 34.5× · Pricier than 75% of peers
P/B 0.61× · Cheaper than 75% of peers
P/S (TTM) 0.71× · Cheaper than median
P/FCF 11.5× · Pricier than 75% of peers
EV/EBITDA 4.6× · Cheaper than 75% of peers
PEG 4.09× · Pricier than 75% of peers

Snowflake

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

VALUE 0 · sector 25
FUTURE 21 · sector 24
PAST 32 · sector 30
HEALTH 87 · sector 90
DIVIDEND 25 · sector 38

VALUE 0: the price sits above our fair-value range.

Insider activity: 45/100

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.

Similar stocks

10 more Medical Care Facilities stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).

Stock Price Fair Value vs Fair Value
HCA Healthcare, Inc HCA $414.59 $547.67 +32%
Fresenius SE FRE €46.82 €32.15 -31%
Dr. Sulaiman Al Habib Medical Services Group 4013 235.00 SAR 112.37 SAR -52%
Tenet Healthcare Corporation THC $266.79 $330.25 +24%
Rede D'Or São Luiz S.A RDOR3 R$33.97 R$47.31 +39%
Apollo Hospitals Enterprise Limited APOLLOHOSP ₹8,565 ₹2,955 -65%
Aier Eye Hospital Group 300015 ¥8.87 ¥7.67 -14%
Max Healthcare Institute Limited MAXHEALTH ₹1,008 ₹284.87 -72%
Bangkok Dusit Medical Services Public Company BDMS 19.70 THB 18.57 THB -6%
Fortis Healthcare Limited FORTIS ₹906.15 ₹300.29 -67%

Compare IHH Healthcare Berhad, an investment holding company, with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Frequently asked questions

Is IHH Healthcare Berhad, an investment holding company, (5225) overvalued or undervalued?
As of Aug 13, 2026, our model estimates a fair value of 4.61 MYR versus a price of 8.27 MYR, about −44% (overvalued).
What is the fair value of 5225?
Our model-based fair value for IHH Healthcare Berhad, an investment holding company, is 4.61 MYR (as of Aug 13, 2026), built from audited fundamentals. The current price is 8.27 MYR.
What is the quality score of 5225?
IHH Healthcare Berhad, an investment holding company, has a Quality Score of 50/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the revenue of IHH Healthcare Berhad, an investment holding company, (5225)?
IHH Healthcare Berhad, an investment holding company, reported trailing-twelve-month revenue of about 26.0B MYR (latest available figure, as of Aug 13, 2026).
What is the net profit margin of 5225?
The net profit margin of IHH Healthcare Berhad, an investment holding company, is about 8.1%, meaning it keeps roughly 8.1% of revenue as net income. Based on the latest reported figures.
Does IHH Healthcare Berhad, an investment holding company, pay a dividend?
IHH Healthcare Berhad, an investment holding company, currently shows a dividend yield of about 1.22% relative to its recent price (as of Aug 13, 2026).

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.

14 days Pro free · no card

Track IHH Healthcare Berhad, an investment holding company, and try Pro for 14 days

One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.

Zero risk: nothing is ever charged. After 14 days you decide whether to stay.